Background and objective: While several studies have found that prescribing practices do not conform to chronic obstructive pulmonary disease (COPD) treatment guidelines, none have examined longitudinal patterns of use of long-acting beta 2 -agonist (LABA) and long-acting muscarinic antagonist (LAMA) therapy across an entire country. We undertook a nationwide follow-up study to describe treatment patterns in new users of long-acting bronchodilators. Methods: National health and pharmaceutical dispensing data were used to identify patients aged ≥45 years who initiated LABA and/or LAMA therapy for COPD between 1 February 2006 and 31 December 2013. Dispensings of LABAs, LAMAs and inhaled corticosteroids (ICSs) were aggregated into episodes of use of therapeutic regimens. Kaplan-Meier curves, sunburst plots and sequence index plots were generated to summarize, respectively, the duration of the first regimen, the sequences in which unique regimens were used and the patterns of use and non-use during follow-up. Results: The study cohort included 83 435 patients with 290 400 person-years of follow-up. The most commonly initiated regimen was a LABA with an ICS. ICS use was inconsistent with international guidelines: over-and under-treatment occurred in patients with infrequent and frequent exacerbations, respectively, and ICS monotherapy was common. The median duration of the first regimen was 46 days. Many patients used multiple regimens over time and periods of non-use were common. Conclusion: In this nationwide study, patterns of use of LABAs, LAMAs and ICSs were complex and often did not comply with treatment guidelines. Further work is required to address the discrepancy between guidelines and prescribing practices.
INTRODUCTION
The 2017 update of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, like earlier versions, advocates the stepwise introduction of long-acting bronchodilators in patients with chronic obstructive pulmonary disease (COPD) who have more than occasional symptoms;
1 the guidelines recommend initial use of a long-acting beta 2 -agonist (LABA) or a long-acting muscarinic antagonist (LAMA), and the subsequent addition of a second long-acting bronchodilator in patients with persistent symptoms. For those with a history of frequent exacerbations, a long-term inhaled corticosteroid (ICS) may be prescribed in conjunction with a LABA; however, long-term ICS monotherapy is not recommended.
SUMMARY AT A GLANCE
In this nationwide follow-up study of patients initiating long-acting beta 2 -agonist (LABA) and/or longacting muscarinic antagonist therapy (LAMA) for chronic obstructive pulmonary disease, the most common first regimen was a LABA with an inhaled corticosteroid (ICS). ICS use was inconsistent with guidelines. There were complex therapy patterns, including periods of non-use.
Recent studies in diverse settings have found that prescribing practice does not conform to international or national COPD treatment guidelines, or drug licencing conditions. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] However, these investigations have been based on subgroups of patients drawn from selected general practices, health insurance databases, or respiratory outpatient clinics or hospitals, and none have examined the longitudinal patterns of use of long-acting bronchodilator therapy in new users across an entire country.
We undertook a nationwide study to describe the patterns of use of LABA, LAMA and ICS therapy in New Zealand patients aged ≥45 years who initiated long-acting bronchodilator therapy for COPD during an 8-year period.
METHODS

Data sources
The study was based on linked health and pharmaceutical dispensing data provided by the Ministry of Health. New Zealand has a universal healthcare system with comprehensive funding of pharmaceuticals, and the Ministry holds several national datasets, including the Pharmaceutical Collection (PHARMS, records of all claims by community-based pharmacists for government-funded dispensings of prescription drugs-virtually all dispensings in New Zealand), 16 National Minimum Dataset (NMDS, hospital discharges from 1988), 17 Cancer Registry, Mortality Collection (hospital-and community-based deaths) 18 and National Health Index (NHI) Collection (demographic information indexed to the NHI, a unique patient identifier). 19 Diagnoses in the NMDS, Cancer Registry and Mortality Collection are coded using successive revisions of the International Statistical Classification of Diseases and Related Health Problems, Australian Modification (ICD-AM).
Identification of the study cohort
The steps undertaken to identify the study cohort are shown in Figure 1 . The Ministry of Health provided data for all patients who were dispensed a LAMA, LABA or LABA/ICS combination product at least once between 1 February 2005 and 31 December 2013. We then excluded patients with incorrectly linked records; those aged <45 years when first dispensed a long-acting bronchodilator (cohort entry date) and those with a history of ≥1 hospital discharge diagnosis of asthma (ICD-9-AM 493, or ICD-10-AM J45 or J46) but no COPD (ICD-9-AM 4912 or ICD-10-AM J44) diagnoses (to exclude patients who might have initiated LABA or LABA/ICS therapy solely for asthma); and those dispensed a long-acting bronchodilator between 1 February 2005 and 31 January 2006 (to exclude prevalent users). The study was approved by the Southern Health and Disability Ethics Committee (reference: 15/STH/66).
Summarizing long-acting bronchodilator and ICS exposure
For each cohort member, we summarized exposure to LAMA, LABA and LABA/ICS therapy during follow-up employing a similar approach to one we have used previously. 20, 21 First, we combined the dispensing data relating to individual products into continuous episodes of use; a continuous episode was defined as a series of dispensings in which the elapsed time between the end date of one dispensed supply and the start date of the next was ≤30 days (Fig. 2) . To calculate the end date of a dispensed supply, we assumed that the duration of exposure was the number of days the dispensed product would have lasted if the recommended daily dose was used (according to contemporaneous MIMS New Zealand publications 22 ); if the recommended dose was given as a range (e.g. 1-2 puffs twice a day), we assumed exposure to the higher dose. Episodes were censored at the earlier of death or at the end of the study period. Second, we summarized the continuous episodes of use of individual products into continuous episodes of use of drug classes (LAMA, LABA or LABA/ICS combination products). We also summarized continuous episodes of use of ICS products after cohort entry. Finally, we aggregated the data into continuous episodes of use of therapeutic regimens. In total, there were eight regimens to which cohort members could have been exposed initially: LABA monotherapy, LAMA monotherapy, LABA/ICS, LABA + ICS, LAMA + ICS, LAMA + LABA, LAMA + LABA/ICS and LAMA + LABA + ICS. We also documented episodes of ICS monotherapy during followup. The LABAs which were available in New Zealand during the study period were salmeterol and formoterol, the LABA/ICS products were salmeterol/fluticasone and formoterol/budesonide, and tiotropium was the sole LAMA.
Other relevant information
Demographic data (date of birth, sex, prioritized ethnicity 23 and an area-based measure of socio-economic position, NZDep2006 24 ) and hospital discharge diagnoses were obtained from the NHI Collection and NMDS, respectively. Information about the use of other prescription drugs was extracted from the PHARMS data. We derived a Charlson co-morbidity score for each cohort member at entry based on hospital discharge diagnoses in the preceding 5 years, using an ICD-10 SAS macro developed by others. 25 We categorized COPD severity at cohort entry as 'very severe', 'severe' or 'mild/moderate' according to an adapted version of an algorithm used elsewhere (see Table S1 , Supplementary Information). 26 
Statistical analysis
Kaplan-Meier curves were plotted to summarize the duration of the first regimen, using the survival package in R 3.3.3.
27
For each cohort member, we identified the sequence in which unique regimens were introduced, counting only the first exposure to any given regimen and those regimens with a duration ≥15 days. Sunburst plots were generated to illustrate the order in which these regimens were used in the first 1, 2 and 3 years of follow-up, using methods described by others; 28 data were restricted to those with at least 1, 2 and 3 years of follow-up, respectively.
Sequence index plots for weekly regimen use in the first year of follow-up by cohort members who initiated LABA monotherapy, LAMA monotherapy, LABA + ICS or LABA/ICS were generated with the TraMineR 2.0-5 29 package in R 3.3.3. 27 Weekly use was derived from daily regimen data by taking the modal regimen for a 7-day period. If two regimens were equally common, the first in alphabetical order was used. 
RESULTS
In total, 83 435 patients met the criteria for inclusion in the cohort (Fig. 1) . Overall, there were 290 400 person-years of follow-up and 161 051 person-years of exposure to any therapeutic regimen (including ICS monotherapy) during the study period.
The characteristics of the study population at cohort entry, overall and by first regimen, are shown in Table 1 . Overall, the median age was 64.6 years (interquartile range: 55.4-73.9); just under half of the cohort members were male; about three quarters were New Zealand European, 13% were M aori and about 4% belonged to Pacific and Asian ethnic groups; and higher proportions were found in the more versus less deprived quintiles. Nearly 80% were classified as having mild/moderate COPD, while about 14% and 7% were classified as severe and very severe, respectively.
The regimens which were most frequently dispensed at cohort entry were those involving a LABA in combination with an ICS (64.8% overall), followed by LABA monotherapy (21.4%) and LAMA monotherapy (10.6%) ( Table 1) . Initiation of both a LABA and LAMA (+/− an ICS) was uncommon. Overall, for 69.8% of patients with mild/moderate COPD, the initial regimen included an ICS, while only 58.0% of those with very severe disease commenced such a regimen. Between 2006 and 2013, there was a progressive increase (from 50.9% to 72.8%) in the proportion of patients with very severe COPD who were started on an ICS-containing regimen; however, an increase was also observed in those with mild/ moderate disease (from 64.8% to 79.8%).
The duration of the first regimen is shown in Figure 3 . For each of the regimens, the median duration was less than a year; the median duration for any regimen was 46 days, while for both LABA monotherapy and LAMA + LABA it was only 31 days.
The proportions and sequence of use of unique regimens during follow-up are shown in Figure 4 . Among cohort members with at least 1 year of follow-up, about half had used ≥2 different regimens of ≥15 days' duration during the first year (Fig. 4A) . The number of unique regimens used increased progressively in those with 2 and 3 years of follow-up (Fig. 4B,C, respectively) , with a small proportion of patients having used ≥5 regimens. Among those who commenced LABA or LAMA monotherapy, the most frequent next therapeutic step was the addition of an ICS rather than a second long-acting bronchodilator. Table S2 (Supplementary Information) shows the characteristics of cohort members who were dispensed ≥3 different regimens during follow-up. Such use increased with increasing age, deprivation and COPD severity. However, similar proportions of males and females, and European, M aori and Pacific patients used multiple regimens. Use of ≥3 different regimens was less common among Asian and 'Other' ethnic groups, although the numbers were small.
The sequence index plots (Fig. 5 ) illustrate complex patterns of use of regimens in the first year of follow-up for those who commenced treatment with one of the four most common regimens, including switches back to previously used regimens and periods of no use.
DISCUSSION
In this nationwide study of patients aged ≥45 years who commenced long-acting bronchodilator therapy for COPD, the most commonly initiated regimen was a LABA with an ICS. About 70% of patients with mild/ moderate COPD were started on an ICS-containing regimen, while about 40% of those with very severe disease were not. Although appropriate use of ICS therapy increased during the study period for patients with very severe COPD, so too did inappropriate use in patients with mild/moderate disease. Many patients used several different regimens over time and periods of nonuse were common.
A key strength of this study is that, unlike previous investigations of the use of long-acting bronchodilators in patients with COPD, we used linked health and pharmaceutical dispensing data which covered an entire country. We were also able to examine changes in treatment regimens during follow-up. Because pharmacists are not reimbursed for dispensings unless they submit a claim, it is likely that we identified virtually all long-acting bronchodilator and ICS community-based dispensings during the study period. Hospital inpatient dispensings are not recorded in PHARMS; however, the Values are numbers and percentages unless stated otherwise. † Less than 3% of cohort members had been discharged from hospital before cohort entry with a diagnosis of benign prostatic hypertrophy or bladder outflow obstruction, close angle glaucoma, hyperthyroidism, ischaemic stroke, transient ischaemic attack or osteoporotic fracture.
ICS, inhaled corticosteroid; IQR, interquartile range; LABA, long-acting beta 2 -agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting beta mean inpatient stay for patients with COPD in 2012/ 2013 was only 4.37 days 30 and patients obtain any newly prescribed drugs from community pharmacies on discharge, so the absence of inpatient data is unlikely to have had an impact on our findings.
At the time the study was initiated, linked data were only available up to December 2013, so we were unable to examine patterns of use of LAMA/LABA combination products (funded since March 2016). This could be addressed in future work. We did not have access to primary care data which meant we were unable to follow patients from the date COPD was first diagnosed and therefore to explore time to initiation of longacting bronchodilator therapy. However, this was not an a priori aim of the study. Moreover, there is some evidence that the date of COPD diagnosis in general practice records may not provide a reliable indication of when the disease was first diagnosed, as COPD regimens are frequently prescribed before the recorded diagnosis date. 8, 31 We did not have information about respiratory symptoms, smoking or spirometry results, and while we confined our study to new users of longacting bronchodilators aged ≥45 years and excluded individuals with ≥1 hospital discharge diagnosis of asthma and no diagnoses of COPD, the absence of these data means we cannot completely rule out the possibility that the cohort included a small number of patients who had asthma but not COPD. However, our finding that ICS monotherapy of ≥15 days' duration during follow-up was relatively common (33.2% of the cohort had ≥1 episode) cannot be fully explained by any inadvertent inclusion of patients with asthma only-such use was observed in 34.7% of cohort members who had a hospital discharge diagnosis of COPD before or during follow-up, 28.6% of those who initiated or used a LAMA-containing regimen during follow-up (LAMA therapy was only available for patients with spirometry-confirmed COPD during the study period 32 ) and 24.5% of patients who were not dispensed an ICS in the 6 months before cohort entry. Nor can it be explained, for those taking LABA + ICS, by the inadvertent underestimation of the duration of LABA use in those who were prescribed less than our defined standard daily dose; in a validation exercise based on the subset of dispensings in which the days' supply of LABA was recorded in PHARMS, we found good agreement between our estimated days' supply and the value recorded in PHARMS. Moreover, the duration of 77% of ICS monotherapy episodes was >30 days.
The overall finding of this study-that the prescribing of long-acting bronchodilators and ICSs in patients with COPD does not appear to align with GOLD guidelines [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] -is consistent with recent studies based on subgroups of patients in a variety of settings. Our observation that the most commonly dispensed first regimen involving a long-acting bronchodilator was a LABA in combination with an ICS is consistent with findings from Spain, 14 the Netherlands 33 and some, 8, 11, 13, 34, 35 but not all, 15 studies based in the UK. In several studies, researchers have had access to detailed clinical information which enabled them to assess the appropriateness of ICS use and subsequently conclude that ICS therapy was being overused. [2] [3] [4] [5] [6] [12] [13] [14] [15] In line with our findings, previous investigations have also observed the use of ICS monotherapy in patients with COPD, including studies based on primary care databases in the UK 4, 6, 8, [11] [12] [13] 15 and Spain, 14 patients attending respiratory clinics in Italy, 2 patients followed after discharge from hospital with a diagnosis of COPD in Italy 9 and members of a health insurance database in the USA. 7 Future studies may need to account for prescribing practices related to sub-phenotypes of COPD, such as overlap syndromes, in which ICS may be prescribed at an earlier stage. 36 
Figure 5
Sequence index plots for weekly regimen use in the first year of follow-up. Plots are shown for cohort members who initiated LABA monotherapy, LAMA monotherapy, LABA + ICS and LAMA/ICS. The data which are plotted include all regimens used during the follow-up period (including regimens <15 days' duration and the re-initiation of, or switching back to, regimens used earlier in the observation period), as well as periods in which no regimens were used (white space). ICS, inhaled corticosteroid; LABA, longacting beta 2 -agonist; LAMA, long-acting muscarinic antagonist.
Our finding of complex patterns of use of therapeutic regimens during follow-up along with periods of nonuse is also consistent with findings from elsewhere. 7, 9, [33] [34] [35] In this study of patients with COPD living in New Zealand, patterns of use of LABAs, LAMAs and ICSs were complex: individual patients used multiple regimens over time and periods of non-use were common. ICS use was inconsistent with guidelines: ICS monotherapy was common, and over-and undertreatment with ICS in combination with a long-acting bronchodilator occurred in patients with infrequent and frequent exacerbations, respectively. Although under-treatment declined over time, over-treatment increased. In developing guidelines, and strategies to improve their implementation, there is a need to explore and address the reasons for the long-standing discrepancy between guideline recommendations and prescribing practices.
